X
- No products in the list
The EZER™ SARS-CoV-2 /Flu/RSV/ADV Antigen Combo Rapid Test is a chromatographic lateral flow immunoassay for the qualitative detection of SARS-CoV-2, Influenza A, Influenza B, RSV, and Adenovirus antigens from nasal or nasopharyngeal swab specimens. Optimized for early-stage infection, the test detects viral antigens within the first 7 days after symptom onset, when respiratory viral shedding is highest and rapid differentiation is clinically critical.
By enabling simultaneous multi-pathogen detection in a single workflow, the test simplifies differential diagnosis in patients presenting with influenza-like illness. Results are available within 15 minutes, allowing healthcare professionals to initiate appropriate infection control measures, treatment pathways, or confirmatory testing without delay.
Clinical evaluation against PCR reference methods demonstrated high sensitivity, specificity, and overall percent agreement across all five targets. The combination of speed, accuracy, and broad respiratory coverage makes this assay a reliable frontline diagnostic solution for seasonal outbreaks, emergency care, and routine respiratory screening
Each kit contains:
20 EZER™ SARS-CoV-2 / Flu / RSV / ADV test devices
20 sterile nasal/nasopharyngeal swabs
20 extraction tubes with buffer
1 tube stand
1 package insert with instructions
The test detects viral antigens through immunochromatographic analysis. If one or more target antigens are present in the specimen, a red line appears in the corresponding test region alongside the control (C) line, confirming a valid result.
SARS-CoV-2, Influenza viruses, RSV, and Adenovirus are major causes of acute respiratory illness with overlapping clinical symptoms. Viral antigens are typically detectable in upper respiratory samples during the early phase of infection, before viral load declines. Antigen-based detection:
Enables rapid differentiation of respiratory pathogens
Supports early isolation and infection control decisions
Improves patient triage during peak respiratory seasons
Provides actionable results when molecular testing is not immediately available
Because antigen positivity reflects active viral presence, this test is most effective during the first days after symptom onset, when clinical intervention has the greatest impact.
Developed by Genesis Biotech, this assay incorporates virus-specific monoclonal antibodies conjugated to colloidal gold particles. The test is designed to detect:
SARS-CoV-2 nucleocapsid antigen
Influenza A and Influenza B antigens
RSV antigen
Adenovirus antigen
Performance summary (PCR comparison):
High positive and negative percent agreement across all targets
No observed cross-reactivity between SARS-CoV-2, Flu A/B, RSV, and ADV
No significant interference from common respiratory microorganisms
Sample types:
Nasal swab
Nasopharyngeal swab
Test procedure:
Extract the collected swab sample in extraction buffer
Add extracted sample drops to each test well
Read results after 15 minutes
Result interpretation:
Positive: Control line (C) + virus-specific test line
Negative: Control line (C) only
Invalid: No control line — retest required
The cassette-based format and rapid read time support efficient testing in both clinical and point-of-care environments.
The EZER™ SARS-CoV-2 /Flu/RSV/ADV Antigen Combo Rapid Test is intended for:
Differential diagnosis of acute respiratory infections
Emergency department and outpatient screening
Seasonal respiratory virus surveillance
Hospital and community testing programs
By combining speed, accuracy, and multi-target detection in one assay, this test helps healthcare providers optimize patient management, reduce diagnostic uncertainty, and improve infection control outcomes.
Product Catalogus
For any missing information or if you require additional details, please do not hesitate to contact us.